These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 9387205)

  • 21. Essential thrombocythemia/polycythemia vera and pregnancy: the need for an observational study in Europe.
    Griesshammer M; Struve S; Harrison CM
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):422-9. PubMed ID: 16810618
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic options for essential thrombocythemia and polycythemia vera.
    Solberg LA
    Semin Oncol; 2002 Jun; 29(3 Suppl 10):10-5. PubMed ID: 12096352
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New drugs in essential thrombocythemia and polycythemia vera.
    Tefferi A; Elliott MA; Solberg LA; Silverstein MN
    Blood Rev; 1997 Mar; 11(1):1-7. PubMed ID: 9218101
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Philadelphia chromosome negative chronic myeloproliferative disorders: a practical overview.
    Tefferi A
    Mayo Clin Proc; 1998 Dec; 73(12):1177-84. PubMed ID: 9868417
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Use of interferon in patients with hairy cell leukemia and myeloproliferative disorders].
    Skotnicki AB; Wolska-Smoleń T
    Acta Haematol Pol; 1994; 25(2 Suppl 1):124-35. PubMed ID: 8067197
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols.
    Berk PD; Goldberg JD; Donovan PB; Fruchtman SM; Berlin NI; Wasserman LR
    Semin Hematol; 1986 Apr; 23(2):132-43. PubMed ID: 3704665
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of alpha interferon and hydroxyurea in late phase refractory myeloproliferative disease.
    Litam PP; Landaw SA; Zamkoff KW
    Haematologia (Budap); 1994; 26(2):87-90. PubMed ID: 7890266
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnosis and treatment of polycythemia vera and possible future study designs of the PVSG.
    Michiels JJ; Barbui T; Finazzi G; Fuchtman SM; Kutti J; Rain JD; Silver RT; Tefferi A; Thiele J
    Leuk Lymphoma; 2000 Jan; 36(3-4):239-53. PubMed ID: 10674896
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms.
    Hasselbalch HC
    Expert Rev Hematol; 2011 Dec; 4(6):637-55. PubMed ID: 22077528
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Front-line therapy in polycythemia vera and essential thrombocythemia.
    Barbui T; Finazzi MC; Finazzi G
    Blood Rev; 2012 Sep; 26(5):205-11. PubMed ID: 22784966
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnosis and therapy of polycythemia vera.
    Lengfelder E; Merx K; Hehlmann R
    Semin Thromb Hemost; 2006 Apr; 32(3):267-75. PubMed ID: 16673281
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current opinion in essential thrombocythemia: pathogenesis, diagnosis, and management.
    Tefferi A; Murphy S
    Blood Rev; 2001 Sep; 15(3):121-31. PubMed ID: 11735160
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnosis and treatment of thrombocythemia in myeloproliferative disorders.
    Gilbert HS
    Oncology (Williston Park); 2001 Aug; 15(8):989-96, 998; discussion 999-1000,1006,1008. PubMed ID: 11548978
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment options for essential thrombocythemia and polycythemia vera.
    Vannucchi AM; Guglielmelli P; Pieri L; Antonioli E; Bosi A
    Expert Rev Hematol; 2009 Feb; 2(1):41-55. PubMed ID: 21082994
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk of leukemic transformation in PV and ET patients.
    Chomienne C; Rain JD; Brière J;
    Pathol Biol (Paris); 2004 Jun; 52(5):289-93. PubMed ID: 15217716
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A clinical update in polycythemia vera and essential thrombocythemia.
    Tefferi A; Solberg LA; Silverstein MN
    Am J Med; 2000 Aug; 109(2):141-9. PubMed ID: 10967156
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.
    Michiels JJ; Berneman Z; Schroyens W; Koudstaal PJ; Lindemans J; Neumann HA; van Vliet HH
    Platelets; 2006 Dec; 17(8):528-44. PubMed ID: 17127481
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Interferon therapy in essential thrombocythemia].
    Seewann HL
    Wien Med Wochenschr; 1993; 143(16-17):420-4. PubMed ID: 8273365
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evidence-based management of polycythemia vera.
    Barbui T; Finazzi G
    Best Pract Res Clin Haematol; 2006; 19(3):483-93. PubMed ID: 16781485
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Moving toward disease modification in polycythemia vera.
    Bewersdorf JP; How J; Masarova L; Bose P; Pemmaraju N; Mascarenhas J; Rampal RK
    Blood; 2023 Nov; 142(22):1859-1870. PubMed ID: 37729609
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.